Psoriatic Arthritis Treatment Market
Psoriatic arthritis is a chronic inflammatory arthritis that occurs in conjunction with psoriasis. It is estimated that around 30% of people with psoriasis may develop psoriatic arthritis. The disease causes pain, stiffness and swelling in and around the joints. Over time, psoriatic arthritis can cause permanent damage to the joints. Conventional treatments including disease-modifying antirheumatic drugs (DMARDs) such as methotrexate and TNF inhibitors are used to manage the symptoms. Global psoriatic arthritis treatment market growth is driven by rising development and approval of novel targeted biologic therapies with better safety and efficacy profiles.
Market Dynamics:
Global psoriatic arthritis treatment market growth is driven by growing prevalence of psoriatic arthritis worldwide. According to estimates, the global prevalence of the disease ranges between 0.06% to 1%. Moreover, increasing awareness about the disease and availability of advanced treatments can also drive the market growth. However, high cost of biologic therapies can hamper the market growth, especially in price-sensitive developing regions. Continued efforts by market players to develop cost-effective generic versions of biologics can reduce costs over time. Furthermore, rising healthcare expenditures in emerging nations can offer new opportunities for the market players in the near future.
Key features of the study:
- This report provides in-depth analysis of the global psoriatic arthritis treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global psoriatic arthritis treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer, Johnson & Johnson, AbbVie, Novartis, UCB, Eli Lilly, Bristol-Myers Squibb
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global psoriatic arthritis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global psoriatic arthritis treatment market
Detailed Segmentation-
Detailed Segmentation-
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
